Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -73,876 | -48,722 | -254,789 | 20,170 | 68,578 |
| Depreciation Amortization | 265,288 | 240,948 | 248,770 | 242,609 | 244,065 |
| Accounts receivable | -162,155 | 125,799 | -79,071 | -16,310 | 17,199 |
| Other Working Capital | -4,068 | -47,186 | -59,945 | -133,593 | -61,318 |
| Other Operating Activity | 269,910 | 74,738 | 210,135 | 128,944 | 110,477 |
| Operating Cash Flow | $295,099 | $345,577 | $65,100 | $241,820 | $379,001 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | 1,000 | N/A | N/A |
| PPE Investments | -60,340 | -46,801 | -48,795 | -45,939 | -61,836 |
| Net Acquisitions | N/A | N/A | -84,714 | -146,543 | -251,360 |
| Purchase Sale Intangibles | -14,650 | -22,388 | -41,800 | -1,700 | -4,350 |
| Other Investing Activity | -2,656 | -22,388 | -41,800 | -1,700 | -4,350 |
| Investing Cash Flow | $-62,996 | $-69,189 | $-174,309 | $-194,182 | $-317,546 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 48,000 | 219,000 | 85,000 | N/A | N/A |
| Debt Issued | N/A | 217,732 | N/A | N/A | 180,000 |
| Debt Repayment | -188,918 | -414,080 | -123,272 | -78,179 | -37,012 |
| Common Stock Issued | 1,154 | 451 | 662 | 853 | 321 |
| Common Stock Repurchased | N/A | N/A | -1,722 | N/A | N/A |
| Other Financing Activity | -72,027 | -235,676 | -67,288 | -60,796 | -11,502 |
| Financing Cash Flow | $-211,791 | $-212,573 | $-106,620 | $-138,122 | $131,807 |
| Exchange Rate Effect | -999 | 65 | -5,683 | 102 | 1,037 |
| Beginning Cash Position | 99,107 | 35,227 | 256,739 | 347,121 | 152,822 |
| End Cash Position | 118,420 | 99,107 | 35,227 | 256,739 | 347,121 |
| Net Cash Flow | $19,313 | $63,880 | $-221,512 | $-90,382 | $194,299 |
| Free Cash Flow | |||||
| Operating Cash Flow | 295,099 | 345,577 | 65,100 | 241,820 | 379,001 |
| Capital Expenditure | -60,340 | -46,801 | -48,795 | -50,939 | -61,836 |
| Free Cash Flow | 234,759 | 298,776 | 16,305 | 190,881 | 317,165 |